Polypharmacy Management in a Gender Perspective: At the Heart of the Problem: Analysis of Major Cardiac Diseases, SARS-CoV-2 Affection and Gender Distribution in a Cohort of Patients in Internal Medicine Ward.
COVID-19
SARS-CoV-2
cardiovascular disease
gender medicine
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
03 05 2023
03 05 2023
Historique:
received:
22
12
2022
revised:
24
02
2023
accepted:
08
03
2023
medline:
15
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
COVID-19 patients with any pre-existing major cardio-vascular disease (CVD) are at the highest risk of viral infection and of developing severe disease. The pathophysiological mechanism is characterized by the viral link to angiotensin-converting enzyme 2 (ACE2) and the involvement of the endothelial system with the release of cytokines and the inflicting of direct damage to the myocardium, the induction of microthrombosis, and the initiation of alterations in oxygen diffusion. The aim of the study is to analyze the clinical course and outcomes in patients (gender-stratified) with pre-existing major CVD. Out of the 1833 (973 M/860 F) patients admitted to the Internal Medicine COVID-19 Unit of "Castelli Hospital", Lazio, Italy, from 1 January 2021 to 31 December 2021, 600 patients (320 M/280 F) with a mean age of 77 (78.6 M/75.1 F) previously had CVD. Demographic characteristics, length of the stay (LOS) and oxygen therapy were evaluated. All of the CVD COVID-19 patients underwent non-invasive ventilation (NIV). CVD was linked with increased LOS (21 days F/22 M) compared to no CVD (19 days). In total, 32.7% of total patients had major CVD. Timely identification and evaluation of patients with pre-existing major CVD are fundamental for adequate treatment based on gender, severity, state of illness and for risk reduction.
Sections du résumé
BACKGROUND
COVID-19 patients with any pre-existing major cardio-vascular disease (CVD) are at the highest risk of viral infection and of developing severe disease. The pathophysiological mechanism is characterized by the viral link to angiotensin-converting enzyme 2 (ACE2) and the involvement of the endothelial system with the release of cytokines and the inflicting of direct damage to the myocardium, the induction of microthrombosis, and the initiation of alterations in oxygen diffusion. The aim of the study is to analyze the clinical course and outcomes in patients (gender-stratified) with pre-existing major CVD.
METHODS
Out of the 1833 (973 M/860 F) patients admitted to the Internal Medicine COVID-19 Unit of "Castelli Hospital", Lazio, Italy, from 1 January 2021 to 31 December 2021, 600 patients (320 M/280 F) with a mean age of 77 (78.6 M/75.1 F) previously had CVD. Demographic characteristics, length of the stay (LOS) and oxygen therapy were evaluated.
RESULTS
All of the CVD COVID-19 patients underwent non-invasive ventilation (NIV). CVD was linked with increased LOS (21 days F/22 M) compared to no CVD (19 days). In total, 32.7% of total patients had major CVD.
CONCLUSIONS
Timely identification and evaluation of patients with pre-existing major CVD are fundamental for adequate treatment based on gender, severity, state of illness and for risk reduction.
Identifiants
pubmed: 37174229
pii: ijerph20095711
doi: 10.3390/ijerph20095711
pmc: PMC10178862
pii:
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Eur Heart J. 2020 May 14;41(19):1798-1800
pubmed: 32186331
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Arch Bronconeumol. 2003 Mar;39(3):101-5
pubmed: 12622967
J Int Med Res. 2019 Apr;47(4):1429-1440
pubmed: 30799666
Methods. 2021 Nov;195:29-43
pubmed: 33962011
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Int J Environ Res Public Health. 2021 Sep 30;18(19):
pubmed: 34639631
Atherosclerosis. 2015 Jul;241(1):211-8
pubmed: 25670232
J Sleep Res. 2020 Aug;29(4):e13074
pubmed: 32410272
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Clin Med. 2021 Aug 23;10(16):
pubmed: 34442038
Eur J Intern Med. 2015 Dec;26(10):759-65
pubmed: 26365373
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Evol Med Public Health. 2020 Jul 30;2020(1):129-138
pubmed: 32983538
Int J Environ Res Public Health. 2021 Jun 03;18(11):
pubmed: 34204972
Circulation. 2020 May 19;141(20):e810-e816
pubmed: 32216640
Int J Infect Dis. 2020 Sep;98:188-190
pubmed: 32574692
Pharmacol Res. 2020 Aug;158:104906
pubmed: 32461198
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
F1000Res. 2022 Mar 22;11:345
pubmed: 36128553
Drugs. 2020 Dec;80(18):1929-1946
pubmed: 33068263
Virulence. 2021 Dec;12(1):507-508
pubmed: 33494661
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32269085
Front Psychol. 2020 Oct 23;11:566790
pubmed: 33192844
J Clin Med. 2020 May 09;9(5):
pubmed: 32397558
Front Cardiovasc Med. 2020 Oct 09;7:585866
pubmed: 33195473
J Thorac Dis. 2019 Sep;11(Suppl 14):S1761-S1766
pubmed: 31632753
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904